{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:43:11Z","timestamp":1780360991262,"version":"3.54.1"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The aim of this study was to develop a pretherapy PET\/CT-based prediction model for treatment response to ibrutinib in lymphoma patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>One hundred sixty-nine lymphoma patients with 2441 lesions were studied retrospectively. All eligible lymphomas on pretherapy <jats:sup>18<\/jats:sup>F-FDG PET images were contoured and segmented for radiomic analysis. Lesion- and patient-based responsiveness to ibrutinib was determined retrospectively using the Lugano classification. PET radiomic features were extracted. A radiomic model was built to predict ibrutinib response. The prognostic significance of the radiomic model was evaluated independently in a test cohort and compared with conventional PET metrics: SUV<jats:sub>max<\/jats:sub>, metabolic tumor volume, and total lesion glycolysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The radiomic model had an area under the receiver operating characteristic curve (ROC AUC) of 0.860 (sensitivity, 92.9%, specificity, 81.4%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) for predicting response to ibrutinib, outperforming the SUV<jats:sub>max<\/jats:sub> (ROC AUC, 0.519; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.823), metabolic tumor volume (ROC AUC, 0.579; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.412), total lesion glycolysis (ROC AUC, 0.576; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.199), and a composite model built using all 3 (ROC AUC, 0.562; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.046). The radiomic model increased the probability of accurately predicting ibrutinib-responsive lesions from 84.8% (pretest) to 96.5% (posttest). At the patient level, the model's performance (ROC AUC = 0.811; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.007) was superior to that of conventional PET metrics. Furthermore, the radiomic model showed robustness when validated in treatment subgroups: first (ROC AUC, 0.916; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) versus second or greater (ROC AUC, 0.842; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) line of defense and single treatment (ROC AUC, 0.931; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) versus multiple treatments (ROC AUC, 0.824; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We developed and validated a pretherapy PET-based radiomic model to predict response to treatment with ibrutinib in a diverse cohort of lymphoma patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004060","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T18:04:03Z","timestamp":1642010643000},"page":"209-218","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma"],"prefix":"10.1097","volume":"47","author":[{"given":"Jorge E.","family":"Jimenez","sequence":"first","affiliation":[{"name":"Imaging Physics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Dai","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofan","family":"Xu","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Electrical and Computer Engineering, Rice University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Li","sequence":"additional","affiliation":[{"name":"Biostatistics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinsu","family":"Pan","sequence":"additional","affiliation":[{"name":"Imaging Physics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Wang","sequence":"additional","affiliation":[{"name":"Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Electrical and Computer Engineering, Rice University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Electrical and Computer Engineering, The University of Texas at Austin, Austin, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jaffray","sequence":"additional","affiliation":[{"name":"Imaging Physics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Hazle","sequence":"additional","affiliation":[{"name":"Imaging Physics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homer A.","family":"Macapinlac","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wu","sequence":"additional","affiliation":[{"name":"Imaging Physics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"203","DOI":"10.18632\/oncotarget.426","article-title":"Novel targeted therapies for mantle cell lymphoma","volume":"3","year":"2012","journal-title":"Oncotarget"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JOP.2014.002469","article-title":"Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels","volume":"11","year":"2015","journal-title":"J Oncol Pract"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u2206SUVmax","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1148\/radiol.2015142088","article-title":"Imaging for staging and response assessment in lymphoma","volume":"276","year":"2015","journal-title":"Radiology"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2967\/jnumed.113.130609","article-title":"Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients","volume":"55","year":"2014","journal-title":"J Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/MNM.0b013e32832e0c13","article-title":"FDG positron emission tomography\/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome","volume":"30","year":"2009","journal-title":"Nucl Med Commun"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12149-019-01354-9","article-title":"Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in mantle cell lymphoma","volume":"33","year":"2019","journal-title":"Ann Nucl Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ijrobp.2005.02.009","article-title":"Dependence of FDG uptake on tumor microenvironment","volume":"62","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-12-2217","article-title":"Intratumor heterogeneity: evolution through space and time","volume":"72","year":"2012","journal-title":"Cancer Res"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","year":"2013","journal-title":"Nature"},{"key":"bib17-20250621","article-title":"Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy","volume":"S1044-579X(20)30264-9","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s42256-021-00377-0","article-title":"Radiological tumor classification across imaging modality and histology","volume":"3","year":"2021","journal-title":"Nat Mach Intell"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00259-018-4138-5","article-title":"Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","year":"2013","journal-title":"Nature"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.crad.2004.07.008","article-title":"Texture analysis of medical images","volume":"59","year":"2004","journal-title":"Clin Radiol"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2967\/jnumed.110.082404","article-title":"Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2967\/jnumed.119.230037","article-title":"Tumor subregion evolution-based imaging features to assess early response and predict prognosis in oropharyngeal cancer","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1007\/s00259-019-04420-6","article-title":"Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00259-012-2166-0","article-title":"Standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases","volume":"39","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","article-title":"3D slicer as an image computing platform for the quantitative imaging network","volume":"30","year":"2012","journal-title":"Magn Reson Imaging"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"E104","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","year":"2017","journal-title":"Cancer Res"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"e2057","DOI":"10.7717\/peerj.2057","article-title":"DICOM for quantitative imaging biomarker development: a standards based approach to sharing clinical data and structured PET\/CT analysis results in head and neck cancer research","volume":"4","year":"2016","journal-title":"Peer J"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1214\/aos\/1016218223","article-title":"Additive logistic regression: a statistical view of boosting (with discussion and a rejoinder by the authors)","volume":"28","year":"2000","journal-title":"Ann Statist"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","year":"1950","journal-title":"Cancer"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"e92209","DOI":"10.1371\/journal.pone.0092209","article-title":"Area under precision-recall curves for weighted and unweighted data","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jee\/39.2.269","article-title":"Individual comparisons of grouped data by ranking methods","volume":"39","year":"1946","journal-title":"J Econ Entomol"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","year":"1988","journal-title":"Biometrics"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.3324\/haematol.2019.223016","article-title":"Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET project","volume":"105","year":"2020","journal-title":"Haematologica"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3324\/haematol.2019.230649","article-title":"Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma","volume":"105","year":"2020","journal-title":"Haematologica"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","year":"2015","journal-title":"Nat Med"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00259-010-1469-2","article-title":"Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.V126.23.335.335","article-title":"Predictive power of FDG-PET parameters at diagnosis and after induction in patients with mantle cell lymphoma, interim results from the LyMa-PET project, conducted on behalf of the Lysa group","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.semnuclmed.2017.09.005","article-title":"Metabolic tumor volume metrics in lymphoma","volume":"48","year":"2018","journal-title":"Semin Nucl Med"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12032-014-0446-1","article-title":"Predictive value of F-18 FDG PET\/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants","volume":"32","year":"2015","journal-title":"Med Oncol"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1148\/radiol.2016151829","article-title":"Early-stage non-small cell lung cancer: quantitative imaging characteristics of (18)F Fluorodeoxyglucose PET\/CT allow prediction of distant metastasis","volume":"281","year":"2016","journal-title":"Radiology"},{"key":"bib42-20250621","doi-asserted-by":"crossref","first-page":"11707","DOI":"10.7150\/thno.50565","article-title":"Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer","volume":"10","year":"2020","journal-title":"Theranostics"},{"key":"bib43-20250621","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00259-011-1936-4","article-title":"Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET\/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma","volume":"39","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib44-20250621","first-page":"4591","article-title":"Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography","volume":"25","year":"2005","journal-title":"Anticancer Res"},{"key":"bib45-20250621","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","article-title":"Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma","volume":"13","year":"2002","journal-title":"Ann Oncol"},{"key":"bib46-20250621","doi-asserted-by":"crossref","first-page":"e001752","DOI":"10.1136\/jitc-2020-001752","article-title":"Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers","volume":"9","year":"2021","journal-title":"J Immunother Cancer"},{"key":"bib47-20250621","doi-asserted-by":"crossref","first-page":"788","DOI":"10.21037\/qims.2018.09.09","article-title":"Semi-quantitative analysis of pre-treatment morphological and intratumoral characteristics using 18F-fluorodeoxyglucose positron-emission tomography as predictors of treatment outcome in nasal and paranasal squamous cell carcinoma","volume":"8","year":"2018","journal-title":"Quant Imaging Med Surg"},{"key":"bib48-20250621","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13550-020-00686-2","article-title":"Predictive value of quantitative 18F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma","volume":"10","year":"2020","journal-title":"EJNMMI Res"},{"key":"bib49-20250621","doi-asserted-by":"crossref","first-page":"e0210224","DOI":"10.1371\/journal.pone.0210224","article-title":"Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis","volume":"14","year":"2019","journal-title":"PLoS One"},{"key":"bib50-20250621","first-page":"70","article-title":"Interest of FDG-PET in the management of mantle cell lymphoma","volume":"6","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"bib51-20250621","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2018-99-111061","article-title":"Comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-cells alone or in combination with Ibrutinib for relapsed and\/or refractory CLL","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib52-20250621","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.18632\/oncotarget.13873","article-title":"Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18F-FDG PET\/CT in extra-nodal NK\/T-cell lymphoma","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib53-20250621","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10147-020-01807-6","article-title":"The prognostic significance of whole-body and spleen MTV (metabolic tumor volume) scanning for patients with diffuse large B cell lymphoma","volume":"26","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"bib54-20250621","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1182\/blood.V126.23.3918.3918","article-title":"The prognostic value of whole-body SUVmax of nodal and extranodal lesions detected by 18F-FDG PET-CT in patients with extranodal NK\/T-cell lymphoma","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib55-20250621","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"bib56-20250621","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrclinonc.2016.162","article-title":"Imaging biomarker roadmap for cancer studies","volume":"14","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"bib57-20250621","doi-asserted-by":"crossref","first-page":"17286","DOI":"10.1038\/s41598-019-53461-2","article-title":"Deep segmentation networks predict survival of non-small cell lung cancer","volume":"9","year":"2019","journal-title":"Sci Rep"},{"key":"bib58-20250621","doi-asserted-by":"crossref","first-page":"e1153","DOI":"10.1097\/SLA.0000000000003778","article-title":"Development and validation of a deep learning CT signature to predict survival and chemotherapy benefit in gastric cancer: a multicenter, retrospective study","volume":"274","year":"2021","journal-title":"Ann Surg"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:06:25Z","timestamp":1750536385000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004060","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,12]]}}}